Sensing G protein-coupled receptor activation

G protein-coupled receptors (GPCRs) are the key elements of a highly regulated transduction machinery that generates different signaling outcomes to hormones and neurotransmitters. Until recently, it was assumed that diverse ligands of a given GPCR differ only in their ability to alter the balance between the OFF and the ON state of the receptor. However, it has now become evident that their activation mechanisms are more complex and that receptors presumably display distinguishable active conformational states, which are induced by different agonists and correlate to specific signaling outputs. The use of different labeling strategies to insert fluorescent labels into purified, reconstituted receptors, or into receptors in intact cells, has made it possible to sense receptor activation via changes in their fluorescence. Here, we summarize recent progress in the analysis of agonist-dependent activation mechanisms of GPCRs acquired using modern spectroscopic and crystallographic techniques.

[1]  P Ghanouni,et al.  Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  H Weinstein,et al.  Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor , 1997, The EMBO journal.

[3]  A. IJzerman,et al.  Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Liggett,et al.  Chimeric Mutagenesis of Putative G-protein Coupling Domains of the α2A-Adrenergic Receptor , 1996, The Journal of Biological Chemistry.

[5]  M. Bouvier,et al.  The evasive nature of drug efficacy: implications for drug discovery. , 2007, Trends in pharmacological sciences.

[6]  R. Lefkowitz.  The superfamily of heptahelical receptors , 2000, Nature Cell Biology.

[7]  R P STEPHENSON,et al.  A MODIFICATION OF RECEPTOR THEORY , 1997, British journal of pharmacology and chemotherapy.

[8]  Steven O. Smith,et al.  Multiple switches in G protein-coupled receptor activation. , 2009, Trends in pharmacological sciences.

[9]  M. Lohse,et al.  Measurement of the millisecond activation switch of G protein–coupled receptors in living cells , 2003, Nature Biotechnology.

[10]  R. Hennigan,et al.  Fluorescence Resonance Energy Transfer Analysis of Merlin Conformational Changes , 2009, Molecular and Cellular Biology.

[11]  Oliver P. Ernst,et al.  Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.

[12]  B. Kobilka.  G protein coupled receptor structure and activation. , 2007, Biochimica et biophysica acta.

[13]  P. Scheerer,et al.  A G protein-coupled receptor at work: the rhodopsin model. , 2009, Trends in biochemical sciences.

[14]  R. Vogel,et al.  Conformations of the Active and Inactive States of Opsin* , 2001, The Journal of Biological Chemistry.

[15]  M. Bouvier,et al.  Distinct Signaling Profiles of β1 and β2 Adrenergic Receptor Ligands toward Adenylyl Cyclase and Mitogen-Activated Protein Kinase Reveals the Pluridimensionality of Efficacy , 2006, Molecular Pharmacology.

[16]  U. Gether.  Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. , 2000, Endocrine reviews.

[17]  T. Kenakin.  Functional Selectivity through Protean and Biased Agonism: Who Steers the Ship? , 2007, Molecular Pharmacology.

[18]  S. Rasmussen,et al.  The structure and function of G-protein-coupled receptors , 2009, Nature.

[19]  M. Lohse,et al.  Conformational changes in G‐protein‐coupled receptors—the quest for functionally selective conformations is open , 2008, British journal of pharmacology.

[20]  P Ghanouni,et al.  Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2Adrenergic Receptor* , 2001, The Journal of Biological Chemistry.

[21]  M. Scheinin,et al.  Molecular mechanisms of ligand–receptor interactions in transmembrane domain V of the α2A‐adrenoceptor , 2003, British journal of pharmacology.

[22]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[23]  L. Pardo,et al.  Ligand-specific regulation of the extracellular surface of a G protein coupled receptor , 2009, Nature.

[24]  Carsten Hoffmann,et al.  Molecular Basis of Partial Agonism at the Neurotransmitter α2A-Adrenergic Receptor and Gi-protein Heterotrimer* , 2006, Journal of Biological Chemistry.

[25]  R. Zare,et al.  Structure and conformational changes in the C-terminal domain of the beta2-adrenoceptor: insights from fluorescence resonance energy transfer studies. , 2007, The Journal of biological chemistry.

[26]  Pascale G. Charest,et al.  β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Mark H Ellisman,et al.  A FlAsH-based FRET approach to determine G protein–coupled receptor activation in living cells , 2005, Nature Methods.

[28]  Xavier Deupi,et al.  Coupling ligand structure to specific conformational switches in the β2-adrenoceptor , 2006, Nature chemical biology.

[29]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[30]  M. Lohse,et al.  Molecular basis of inverse agonism in a G protein–coupled receptor , 2005, Nature chemical biology.

[31]  I. Hall,et al.  Agonist and Inverse Agonist Actions of β-Blockers at the Human β2-Adrenoceptor Provide Evidence for Agonist-Directed Signaling , 2003 .

[32]  Viktor Hornak,et al.  Helix Movement is Coupled to Displacement of the Second Extracellular Loop in Rhodopsin Activation , 2009, Nature Structural &Molecular Biology.

[33]  H Gobind Khorana,et al.  Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. , 2003, Advances in protein chemistry.

[34]  U. Zabel,et al.  Fluorescence Resonance Energy Transfer Analysis of α2a-Adrenergic Receptor Activation Reveals Distinct Agonist-Specific Conformational Changes , 2009, Molecular Pharmacology.

[35]  P. Leff,et al.  The two-state model of receptor activation. , 1995, Trends in pharmacological sciences.

[36]  Manfred Burghammer,et al.  Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. , 2007, Nature.

[37]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[38]  J. Changeux,et al.  ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. , 1965, Journal of molecular biology.

[39]  S. Liggett,et al.  Identification of a Gs Coupling Domain in the Amino Terminus of the Third Intracellular Loop of the α2A-Adrenergic Receptor , 1995, The Journal of Biological Chemistry.

[40]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[41]  Xavier Deupi,et al.  Probing the β2 Adrenoceptor Binding Site with Catechol Reveals Differences in Binding and Activation by Agonists and Partial Agonists* , 2005, Journal of Biological Chemistry.

[42]  Yang Xiang,et al.  Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. , 2004, The Journal of biological chemistry.

[43]  Thomas M Frimurer,et al.  Ligand binding and micro-switches in 7TM receptor structures. , 2009, Trends in pharmacological sciences.

[44]  Patrick Scheerer,et al.  Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.

[45]  B. Kobilka,et al.  Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. , 1995, The Journal of biological chemistry.

[46]  T. Kenakin.  New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism , 2005, Nature Reviews Drug Discovery.

[47]  V. Arshavsky.  Rhodopsin phosphorylation: from terminating single photon responses to photoreceptor dark adaptation , 2002, Trends in Neurosciences.

[48]  Xavier Deupi,et al.  Conformational complexity of G-protein-coupled receptors. , 2007, Trends in pharmacological sciences.